Cited by 1,509Acute Myocardial Infarction ResearchCardiac Health and Mental HealthCardiac Ischemia and Reperfusion

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

beta Blockade after myocardial infarction: systematic review and meta regression analysis

Open access

Freemantle, N., Cleland, J., Young, P., Mason, J., Harrison, J.·1999·BMJ

DOI 10.1136/bmj.318.7200.1730PMC PMC31101

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVES: To assess the effectiveness of beta blockers in short term treatment for acute myocardial infarction and in longer term secondary prevention; to examine predictive factors that may influence outcome and therefore choice of drug; and to examine the clinical importance of the results in the light of current treatment. DESIGN: Systematic review of randomised controlled trials. SETTING: Randomised controlled trials. SUBJECTS: Patients with acute or past myocardial infarction. INTERVENTION: beta Blockers compared with control. MAIN OUTCOME MEASURES: All cause mortality and non-fatal reinfarction. RESULTS: Overall, 5477 of 54 234 patients (10.1%) randomised to beta blockers or control died. We identified a 23% reduction in the odds of death in long term trials (95% confidence interval 15% to 31%), but only a 4% reduction in the odds of death in short term trials (-8% to 15%). Meta regression in long term trials did not identify a significant reduction in effectiveness in drugs with cardioselectivity but did identify a near significant trend towards decreased benefit in drugs with intrinsic sympathomimetic activity. Most evidence is available for propranolol, timolol, and metoprolol. In long term trials, the number needed to treat for 2 years to avoid a death is 42, which compares favourably with other treatments for patients with acute or past myocardial infarction. CONCLUSIONS: beta Blockers are effective in long term secondary prevention after myocardial infarction, but they are underused in such cases and lead to avoidable mortality and morbidity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.318.7200.1730

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Untitled work
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Sleight, R. B., Sleight, P., Parish, S., Appleby, P. N., Collins, R., & Baigent, C. (1988) · PubMed · Cited by 2,868
Comparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction
The TIMI Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198903093201002 · Cited by 1,024
Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction
Gottlieb, S. S., McCarter, R., & Vogel, R. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390801 · Cited by 966
The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
The Multicenter Diltiazem Postinfarction Trial Research Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190701 · Cited by 828
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
(1994) · Europe PMC (PubMed Central) · Cited by 755
The Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction
Smith, P., Arnesen, H., & Holme, I. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007193230302 · Cited by 637

Show all 34 references

Research works printed but not linked: 3

Viskin S, Barron HV. -Blockers prevent cardiac death following myocar- dial infarction: so why are so many infarct survivors discharge without -blockers? Am J Cardiol 1996;78:821-2.
Spiegelhalter D, Thomas A, Best N, Gilks W. BUGS: Bayesian inference using Gibbs sampling, Version 0.50. Cambridge: Medical Research Council Biostatistics Unit, 1995.
Feely J, de Vane PJ, Maclean D. -Blockers and sympathomimetics. BMJ 1983;286:1043-7.

Sorted by citations

Items 801–900 of 1,000

Cardioselective Beta-Blocker Treatment of Hypertension in Patients with Asthma: When Do Benefits Outweigh Risks?
Self, T. H., Wallace, J. L., & Soberman, J. E. (2012) · Journal of Asthma · doi:10.3109/02770903.2012.719252 · Cited by 10
Should atenolol still be recommended as first-line therapy for primary hypertension?
Karagiannis, A. I., Athyros, V. G., Papageorgiou, A., Τζιόμαλος, Κ., & Elisaf, M. (2006) · PubMed · Cited by 10
Impact of Nontraditional Antiarrhythmic Drugs on Sudden Cardiac Death
Goldberger, J. J., Weinberg, K. M., & Kadish, A. H. (2004) · Elsevier eBooks · doi:10.1016/b0-7216-0323-8/50106-8 · Cited by 10
Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease
Petta, V., Perlikos, F., Loukides, S., Bakakos, P., Chalkias, A. F., Iacovidou, N. M., Xanthos, T. T., Tsekoura, D., & Hillas, G. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9646-z · Cited by 10
AUTONOMIC PHARMACOLOGY
Lymperopoulos, A., & Koch, W. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50013-5 · Cited by 10
The Recent History of Platelets in Thrombosis and Other Disorders
Reynolds, L., & Em, T. (2005) · Queen Mary Research Online (Queen Mary University of London) · Cited by 10
Baroreflex sensitivity is higher during acute psychological stress in healthy subjects under β-adrenergic blockade
Truijen, J., Davis, S. C. A. T., Stok, W., Kim, Y.-S., van Westerloo, D. V., Levi, M., van der Poll, T., Westerhof, B., Karemaker, J., & van Lieshout, J. (2010) · Clinical science · doi:10.1042/cs20100137 · Cited by 10
??-Blockers in the Management of Hypertension in Patients with Type 2 Diabetes Mellitus
Dunne, F., Kendall, M. J., & Martin, U. (2001) · Drugs · doi:10.2165/00003495-200161040-00001 · Cited by 10
Opportunities for control of coronary heart disease in Australia
McElduff, P., Dobson, A. J., Jamrozik, K. D., & HOBBS, M. S. T. (2001) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1467-842x.2001.tb00545.x · Cited by 10
Lifestyle Medicine Strategies for Risk Factor Reduction, Prevention, and Treatment of Coronary Heart Disease: Part II
Rippe, J. M., Angelopoulos, T. J., & Zukley, L. M. (2007) · American Journal of Lifestyle Medicine · doi:10.1177/1559827606297759 · Cited by 10
The pharmacoeconomics of peri‐operative beta‐blocker therapy
Biccard, B. M., Sear, J. W., & Foëx, P. (2005) · Anaesthesia · doi:10.1111/j.1365-2044.2005.04401.x · Cited by 10
Prevention of risk factors: beta-blockade and hypertension
Mancia, G. (2009) · European Heart Journal Supplements · doi:10.1093/eurheartj/sup003 · Cited by 10
Cautionary tales in the interpretation of systematic reviews of therapy trials
Scott, I. A., Greenberg, P., Poole, P., & Campbell, D. A. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01140.x · Cited by 10
Changes in the baseline characteristics, management and outcomes of acute myocardial infarction in Estonia
Blöndal, M. (2012) · DSpace repository (University of Tartu) · Cited by 10
Effect of beta blocker withholding or withdrawal after myocardial infarction without reduced ejection fraction on ischaemic events: a post hoc analysis from the REBOOT trial
Rosselló, X., Sánchez, P. L., Owen, R., Raposeiras‐Roubín, S., Poletti, F., Barrabés, J. A., Anguita, M. P., Domínguez‐Rodríguez, A., Lombardi, M., Pocock, S., et al. (2025) · EuroIntervention · doi:10.4244/eij-d-25-00826 · Cited by 9
Cost-Effectiveness of Posthospital Management of Acute Coronary Syndrome: A Real-World Investigation From Italy
Rea, F., Ronco, R., Martini, N., Maggioni, A. P., & Corrao, G. (2021) · Value in Health · doi:10.1016/j.jval.2021.07.015 · Cited by 9
Use of fat-fed rats to study the metabolic and vascular sequelae of obesity and beta-adrenergic antagonism.
Frye, M. A., McMurtry, I. F., Orton, E. C., & Fagan, K. (2009) · PubMed Central · Cited by 9
Differential Effect of β‐Blockers for Heart Rate Control in Coronary Artery Disease
Cordero, A., Bertomeu‐González, V., Mazón, P., Arribas, J. M., Fácila, L., Bueno, H., González‐Juanatey, J. R., & Bertoméu, V. (2011) · Clinical Cardiology · doi:10.1002/clc.20981 · Cited by 9
A TEN YEAR OVERVIEW OF SURGICAL AND INTERVENTIONAL ARRHYTHMOLOGY IN RUSSIA. SERVICE PECULIAR FEATURES IN THE FAR EAST
Богачевская, С. А., & Николаевич, Б. А. (2017) · Social Aspects of Population Health · doi:10.21045/2071-5021-2017-53-1-1 · Cited by 10
Putative functional genes in idiopathic dilated cardiomyopathy
Nair, N. U., Das, A., Amit, U., Robinson, W., Park, S. G., Basu, M., Lugo, A., Leor, J., Ruppin, E., & Hannenhalli, S. S. (2018) · Scientific Reports · doi:10.1038/s41598-017-18524-2 · Cited by 9
Implications of the New 2017 American College of Cardiology/American Heart Association Guidelines for Hypertension
Aronow, W. S. (2019) · Minerva Cardioangiologica · doi:10.23736/s0026-4725.19.04965-x · Cited by 8
Door to balloon time in primary percutaneous coronary intervention in ST elevation myocardial infarction: every minute counts
Marcusohn, E., Benaim, A. R., Ronen, S., Kerner, A., Beyar, R., & Almog, R. (2022) · Coronary Artery Disease · doi:10.1097/mca.0000000000001145 · Cited by 9
Long term medical treatment of stable coronary disease
Shavelle, D. M. (2007) · Heart · doi:10.1136/hrt.2005.085464 · Cited by 10
A multifaceted intervention to narrow the evidence-based gap in the treatment of acute coronary syndromes: Rationale and design of the Brazilian Intervention to Increase Evidence Usage in Acute Coronary Syndromes (BRIDGE-ACS) cluster-randomized trial
Berwanger, O. B., Guimarães, H. P., Laranjeira, L. N., Cavalcanti, A. B., Kodama, A. A., Zazula, A. D., Santucci, E. V., Victor, E. D. S., Flato, U. A. P., Tenuta, M., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.02.004 · Cited by 9
Treating Cardiac Arrhythmias Detected With an Implantable Cardiac Monitor in Patients After an Acute Myocardial Infarction
Jøns, C., & Thomsen, P. E. B. (2011) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-011-0163-4 · Cited by 9
Management of patients with type 2 diabetes after acute coronary syndromes
Bartnik, M., Malmberg, K., & Rydén, L. (2005) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2005.022 · Cited by 8
Historical perspective and contemporary management of acute coronary syndromes: from MONA to THROMBINS2
Kline, K. P., Conti, C. R., & Winchester, D. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1092374 · Cited by 9
Biocompatible and target specific hydrophobically modified glycol chitosan nanoparticles
Yin, W., Li, W., Rubenstein, D. A., & Meng, Y. (2016) · Biointerphases · doi:10.1116/1.4948265 · Cited by 9
What is the optimal medical management of ischaemic heart failure?
Cleland, J. G. F., John, J., Dhawan, J., & Clark, A. L. (2001) · British Medical Bulletin · doi:10.1093/bmb/59.1.135 · Cited by 9
Self-citation
Reappraisal of β-blocker therapy in the acute and chronic post–myocardial infarction period
Borrello, F., Beahan, M., Klein, L., & Gheorghiade, M. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.01.021 · Cited by 9
The Effects of Different β-Blockers on Left-Ventricular Volume and Function After Primary Coronary Stenting in Acute Myocardial Infarction
Lee, S., Yoon, S.-B., Cho, J.-R., Choi, S., Jung, J.-H., & Lee, N. (2008) · Angiology · doi:10.1177/0003319708315303 · Cited by 9
“The beneficial effects of β-blockers on clinical outcome after acute MI have been shown in prior clinical trials, but many were performed before the introduction of thrombolysis and ACE inhibitors.(10) Recently, in the CAPRICORN trial with a large population treated long term after acute MI and LV dysfunction, it was…”
Method
Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(09)71131-3 · Cited by 9
Einsatz von ?-Blockern bei kardiovaskul�ren Erkrankungen und Asthma bronchiale/COPD
Weiss, T., & Glaab, T. (2004) · Der Internist · doi:10.1007/s00108-003-1093-3 · Cited by 9
Prevention of cardiac complications of non-cardiac surgery: stenosis and thrombosis
Newby, D. E., & Nimmo, A. F. (2004) · British Journal of Anaesthesia · doi:10.1093/bja/aeh096 · Cited by 9
Microextraction-Based Techniques for the Determination of Beta-Blockers in Biological Fluids: A Review
Nisyriou, S., & Zacharis, C. K. (2025) · Separations · doi:10.3390/separations12010014 · Cited by 8
Beta-blocker side-effects in clinical practice: A nationwide approach
Rasmussen, P. V., Strange, J. E., Nielsen, S. K., Hansen, R. B., Gislason, G., Lamberts, M., Hansen, M. L., & Holt, A. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.08.005 · Cited by 9
Acute myocardial infarction in the obstetric patient
Firoz, T., & Magee, L. A. (2012) · Obstetric Medicine · doi:10.1258/om.2011.011080 · Cited by 8
Carbon Nanomaterials-Based Electrically Conductive Scaffolds to Repair the Ischaemic Heart Tissue
Haq, A. U., Carotenuto, F., Trovalusci, F., Matteis, F. D., & Nardo, P. D. (2022) · C – Journal of Carbon Research · doi:10.3390/c8040072 · Cited by 8
Impact of Smoking Reduction on Coronary Heart Disease Mortality Trends During 1981–2000 in England and Wales
Unal, B., Critchley, J., & Capewell, S. (2003) · Tobacco Induced Diseases · doi:10.1186/1617-9625-1-3-185 · Cited by 8
Task Force on Practice Guidelines A Report of the American College of Cardiology Foundation/American Heart Association 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction:
Zhao, D. X.-M., Radford, J., Tamis‐Holland, J. E., Tommaso, C. L., Tracy, C. M., Linderbaum, J. A., Morrow, D. A., Newby, L. K., Ornato, J. P., Fesmire, F. M., et al. (2014) · Cited by 8
Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real‐Life Setting
Bezin, J., Klungel, O. H., Lassalle, R., Dureau‐Pournin, C., Moore, N. D., & Pariente, A. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.864 · Cited by 8
Low Heart Rate Is Associated with Cerebral Pulsatility after TIA or Minor Stroke
Webb, A. J. S., Wartolowska, K. A., Li, L., & Rothwell, P. M. (2022) · Annals of Neurology · doi:10.1002/ana.26480 · Cited by 8
Myocardial infarction (ST-elevation).
Wakai, A. (2009) · Europe PMC (PubMed Central) · Cited by 8
The rationale and design of the B eta‐blocker to LO wer CA rdiovascular D ialysis E vents ( BLOCADE ) F easibility S tudy
Roberts, M. A., Pilmore, H., Ierino, F. L., Badve, S. V., Cass, A., Garg, A. X., Hawley, C. M., Isbel, N. M., Krum, H., Pascoe, E. M., et al. (2014) · Nephrology · doi:10.1111/nep.12362 · Cited by 8
Heart rate and the use of beta-blockers in stable outpatients with coronary artery disease: Polish baseline results of the CLARIFY registry
Stępińska, J., Marona, M., Greenlaw, N., Steg, P. G., & On behalf of the Polish CLARIFY Investigators (2014) · Kardiologia Polska · doi:10.5603/kp.a2014.0134 · Cited by 8
Oh Lord! I've Got Those Clinical Research Blues
Barie, P. S. (2004) · Surgical Infections · doi:10.1089/sur.2004.5.327 · Cited by 8
GNAS Gene Variants Affect β-blocker–related Survival after Coronary Artery Bypass Grafting
Frey, U. H., Muehlschlegel, J. D., Ochterbeck, C., Fox, A. A., Shernan, S. K., Collard, C. D., Lichtner, P., Peters, J., & Body, S. C. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000189 · Cited by 8
Clinical Pharmacology of Antihypertensive Therapy
Taylor, A. A., & Pool, J. L. (2005) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2005.02.006 · Cited by 8
Morphological Effects Induced In Vitro by Propranolol on Human Erythrocytes
Suwalsky, M., Zambrano, P., Villena, F., Manrique-Moreno, M., Gallardo, M. J., Jemioła‐Rzemińska, M., Strzałka, K., Edwards, A. M., Sigrid Mennickent, C., & Dukes, N. (2015) · The Journal of Membrane Biology · doi:10.1007/s00232-015-9780-2 · Cited by 8
Is the Use of β-Blockers in COPD Still an Unresolved Dilemma?
Foresi, A., Cavigioli, G., Signorelli, G., Pozzoni, M. B., & Olivieri, D. (2010) · Respiration · doi:10.1159/000318583 · Cited by 8
Prevention of Coronary Artery Disease: Recent Advances in the Management of Hypertension
Recarti, C., & Unger, T. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0311-2 · Cited by 8
Safety of tiotropium through the Handihaler: why did meta-analyses and database studies appear to give a false alarm?
Barnes, N. C., Jones, P., & Davis, K. J. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205155 · Cited by 8
The use of medications in the secondary prevention of coronary artery disease in the Asian region
Dalal, J. J., Low, L.-P., Phuoc, D. V., Rahman, A. R. A., Reyes, E. B., Soenarta, A. A., & Tomlinson, B. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1010035 · Cited by 8
Effect of different doses of noradrenaline against ischemia-induced ventricular arrhythmias in rat heart in vivo.
Imani, A., Faghihi, M., Keshavarz, M., Karimian, S. M., & Niaraki, S. S. (2009) · PubMed Central · Cited by 8
Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Karagiannis, A. I., Mikhailidis, D. P., Kakafika, A. I., Τζιόμαλος, Κ., & Athyros, V. G. (2006) · Current Pharmaceutical Design · doi:10.2174/138161207779313713 · Cited by 8
“Numerous prospective, randomized studies established the efficacy of -blockers in patients with coronary artery disease (angina or history of myocardial infarction) [6-8], congestive heart failure [9-12] or hypertrophic cardiomyopathy [13].”
Background
DIRETRIZ DE REABILITAÇÃO CARDIOPULMONAR E METABÓLICA: ASPECTOS PRÁTICOS E RESPONSABILIDADES
Cortez, A. A., Ferraz, A. S., da Nóbrega, C. L., Haddad, A., Neder, C. A., Gil, C., de Araújo, S., Roselino, F., Nogueira, G. Â., Teixeira, J. A. C., et al. (2006) · Cited by 8
Evidence of potential bias in a comparison of β blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study
Dong, Y., Alcusky, M. J., Maio, V., Liu, J., Liu, M., Wu, L., Chang, C., Lai, M., & Gagne, J. J. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-012997 · Cited by 8
Intravenous beta-blocker therapy in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention is not associated with benefit regarding short-term mortality: a Swedish nationwide observational study
Mohammad, M. A., Andell, P., Koul, S. M., Desta, L., Jernberg, T., Ömerovic, E., Spaak, J., Fröbert, O., Jensen, J., Engstrøm, T., et al. (2017) · EuroIntervention · doi:10.4244/eij-d-16-01021 · Cited by 8
Prior beta blockers use is independently associated with increased inpatient mortality in patients presenting with acute myocardial infarction
Zhou, Y., Chen, S., Zhu, X., Gui, J., & Abusaada, K. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.004 · Cited by 8
Effect of beta-blocker dose on mortality after acute coronary syndrome
Raposeiras‐Roubín, S., Abu‐Assi, E., Caneiro‐Queija, B., Paz, R. C., Lestón, L. R., Rodríguez, C. G., Lemos, C. G., Vidal, M. B., Guillán, B. O., Martínez, I. P., et al. (2018) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2017.06.022 · Cited by 8
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus
Elharram, M., Sharma, A., White, W. B., Bakris, G. L., Rossignol, P., Mehta, C. R., Ferreira, J. P., & Zannad, F. M. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.014 · Cited by 8
Präoperative Dauertherapie
Buhre, K., de Rossi, L., & Bühre, W. (2005) · Der Anaesthesist · doi:10.1007/s00101-005-0903-5 · Cited by 8
Management of Acute Coronary Syndrome in Diabetes Mellitus
John, J. M., & Bhatt, D. L. (2004) · Herz · doi:10.1007/s00059-004-2614-0 · Cited by 9
Use of time‐dependent measures to estimate benefits of β‐blockers after myocardial infarction
Levy, A. R., Tamblyn, R. M., Abrahamowicz, M., McLeod, P. J., & Fitchett, D. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.944 · Cited by 8
“While some investigators believe that there exists a class effect,(43,44) others believe that important differences exist between -blockers.(2,45,46) Here, over 70% of dispensations were for metoprolol or atenolol, which share a number of pharmacodynamic properties (including high cardioselectivity with no intrinsic s…”
Background
Guía Europea de Prevención Cardiovascular en la Práctica Clínica: Adaptación Española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Álvarez, F. V., Lizcaino, A., et al. (2008) · doi:10.4321/repisalud.5189 · Cited by 8
Intravenous β-blockers in STEMI: what you are about to do, do it quickly
Ibáñez, B. (2020) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872620950205 · Cited by 8
Roles of β-adrenoceptor Subtypes and Therapeutics in Human Cardiovascular Disease: Heart Failure, Tachyarrhythmias and Other Cardiovascular Disorders
Wong, Y. W., Haqqani, H. M., & Molenaar, P. (2024) · Handbook of experimental pharmacology · doi:10.1007/164_2024_720 · Cited by 8
Beta-Blockers After PCI for Stable Coronary Artery Disease and Preserved Left Ventricular Ejection Fraction
Khan, S. U., Akbar, U. A., Khan, M. S., Patel, K. V., Nadeem, A., Thakkar, S., Arshad, H. B., Virani, S. S., Nasir, K., Goel, S. S., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2024.101566 · Cited by 7
Guías 2009 de la Sociedad Chilena de Cardiología para el tratamiento del Infarto Agudo del Miocardio con supradesnivel del ST
Eduardo Guarda, S., Juan Carlos Prieto, D., Patricio Sanhueza, C., Dauvergne, C., René Asenjo, G., & Ramón Corbalán, H. (2009) · Revista chilena de cardiología · doi:10.4067/s0718-85602009000200014 · Cited by 7
Síndromes coronarianas agudas: tratamento e estratificação de risco
Pesaro, A. E. P., Campos, P. C. G. D., Katz, M., Corrêa, T. D., & Knobel, E. (2008) · Revista Brasileira de Terapia Intensiva · doi:10.1590/s0103-507x2008000200014 · Cited by 7
Identification of potential outcome benefit from ACE inhibition after acute coronary syndrome: a biomarker approach using N-terminal proBNP
Squire, I. B., Quinn, P., Narayan, H., Khan, S. Q., Dhillon, O. S., Ng, K., Kelly, D., Davies, J. E., & Ng, L. L. (2010) · Heart · doi:10.1136/hrt.2009.184614 · Cited by 7
2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons Endorsed by the American Association for Clinical Chemistry WRITING COMMITTEE MEMBERS*
Amsterdam, E. A., WENGER, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H. M., Kelly, R. F., Kontos, M. C., et al. (2014) · Cited by 7
Hypertension and stable coronary artery disease
Pedrinelli, R., Ballo, P., Fiorentini, C., Galderisi, M., Ganau, A., Germanò, G., Innelli, P., Paini, A., Perlini, S., Salvetti, M., et al. (2013) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3283609332 · Cited by 7
Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) sobre el manejo del infarto agudo de miocardio con elevación del segmento ST (IAMCEST)
de Werf, F. V., Bax, J. J., Steg, P. G., Marco Tubaro, U., & Weis, M. (2009) · Cited by 7
A review of diagnosis, etiology, assessment, and management of patients with myocardial infarction in the absence of obstructive coronary artery disease
Sharedalal, P., & Aronow, W. S. (2020) · Hospital Practice · doi:10.1080/21548331.2020.1817459 · Cited by 7
“trials evaluating patients with obstructive CAD [4,5,6,7,8].”
Physician-pharmacist collaborative management in patients after percutaneous coronary intervention: a retrospective propensity score matching cohort study
Zhang, Q., Su, H., Li, B., Bai, X., Yan, S., & Li, X. (2021) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01316-0 · Cited by 8
Vaccines and cardiovascular outcomes: lessons learned from influenza epidemics
Yedlapati, S. H., Mendu, A., Tummala, V. R., Maganti, S. S., Nasir, K., & Khan, S. U. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac110 · Cited by 7
Photobiomodulation for Blood Pressure and Heart Rate Reduction in Mastectomized Women on Hormone Blockers: A Randomized Controlled Trial
Pacheco, J. A., Molena, K. F., & Veiga, E. V. (2024) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2023.0136 · Cited by 7
“50 The use of ILIB proceeded without presenting any deleterious effects during clinical research.”
Effect of Combined Beta-Blocker and Angiotensin-Converting Enzyme Inhibitor Treatment on 1-Year Survival After Acute Myocardial Infarction: Findings of the PRIAMHO-II Registry
Arós, F., de Loma-Osorio, A. F., Vila, J., López‐Bescós, L., Cuñat, J., Rodríguez, E., José, J. M. S., Heras, M., & Marrugat, J. (2006) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(06)60767-6 · Cited by 8
Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies
Siddiqui, A. H., & Kowey, P. R. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.hco.0000240591.06839.39 · Cited by 7
Metoprolol, but not atenolol, reduces stress induced neuropeptide Y release in pigs
Åblad, B., Bjurö, T., Björkman, J., Brax, O., Ewaldsson, L., Forshult, E., Lidfors, L., & Lundberg, J. M. (2010) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2010.498923 · Cited by 7
“Heart rate (beats/min) 109 (3)∗# 96 (3) 96 (3) 103 (4)∗# Respiration rate (cycles/min) 23 (3) 21 (3) 18 (3) 20 (4) NPY plasma conc (pM) 58 (18) 41 (12) 73 (19) 49 (7)”
Background
Increasing longevity by decreasing sympathetic stress – early receptor blockade pharmacotherapy
Milne, B., & Hong, M. G. L. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.10.027 · Cited by 7
Clinical pharmacology of beta-blockers in cardiology: trial results and clinical applications
Lechat, P. P. (2008) · Hot Topics in Cardiology · doi:10.4147/htc-081000 · Cited by 7
The role of beta-adrenolytic drugs in treating anxiety disorders
Brudkowska, Ż., Tomczyk, M., Jusiak, K., Karakuła‐Juchnowicz, H., & Rudnicka-Drożak, E. (2018) · Current Problems of Psychiatry · doi:10.2478/cpp-2018-0017 · Cited by 7
Beta-Blockers for the Secondary Prevention of Myocardial Infarction in People with Dementia: A Systematic Review
Lanham, D. A., Ali, S., Davis, D. H. J., & Rawle, M. J. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190503 · Cited by 7
“MI in the general population dates back to the 1960 s 246 [5].”
Managing the elderly patient with hypertension: current strategies, challenges, and considerations
Aronow, W. S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1732206 · Cited by 7
Can beta-blockers be used for people with COPD?
(2011) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2011.01.0003 · Cited by 7
Beta-blockers use from the general to the hemodialysis population
Aoun, M., & Tabbah, R. N. (2019) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.10.003 · Cited by 7
When not to use beta-blockers in seniors with hypertension.
Schumann, S.-A., & Hickner, J. M. (2008) · Europe PMC (PubMed Central) · Cited by 7
Aldosterone Receptor Blockade in Patients with Left Ventricular Systolic Dysfunction Following Acute Myocardial Infarction
Brandimarte, F., Blair, J. E., Manuchehry, A., Fedele, F., & Gheorghiade, M. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2007.08.011 · Cited by 7
“Aldosterone receptor blockade is beneficial in patients with post-MI LVSD who are receiving other therapies such as reperfusion therapy, antiplatelet therapy, beta blockers [62,63], ACE inhibitors [64–66], and ARBs [8,67].”
Background
Review Article: Examining Treatment of ST-Elevation Myocardial Infarction: The Importance of Early Intervention
Lamas, G. A., Escolar, E., & Faxon, D. P. (2010) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248409354600 · Cited by 7
Changes in the management of acute myocardial infarction in Southern Tasmania
McNamara, Peterson, G. M., & Friesen (2000) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2000.00269.x · Cited by 7
“The underutilization of b-blockers after an AMI is of concern world-wide (9, 10).”
Background
Benefits of Optimising Drug Treatment in Home-Dwelling Elderly Patients with Coronary Artery Disease
Strandberg, T. E., Pitkälä, K. H., & Tilvis, R. S. (2003) · Drugs & Aging · doi:10.2165/00002512-200320080-00004 · Cited by 7
Under-diagnosis of diabetes mellitus in patients with coronary artery disease
Kukreja, N., Wilkinson, J., MacDuff, A., Galloway, C. F., & Fox, K. M. (2004) · International Journal of Cardiology · doi:10.1016/j.ijcard.2003.08.012 · Cited by 7
“There are well-established roles for aspirin [1–3], BetaBlockers [4], 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) and Angiotensin-Converting-Enzyme (ACE) inhibitors.”
Background
Underuse of cardioprotective medications in patients prior to acute myocardial infarction
Miller, R. R., Li, Y.-F., Sun, H., Kopjar, B., Sales, A. E., Piñeros, S. L., & Fihn, S. D. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00541-1 · Cited by 7
Omega-3 fatty acids and ventricular arrhythmias: Nothing is simple
Albert, C. M. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.02.001 · Cited by 7
Is Pretreatment with Beta-Blockers Beneficial in Patients with Acute Coronary Syndrome?
Cuculi, F., Radovanović, D., Pedrazzini, G. B., Regli, M., Urban, P. M., Stauffer, J. C., & Erné, P. (2009) · Cardiology · doi:10.1159/000256384 · Cited by 7
Cardiovascular outcomes in the comparative hypertension drug trials: more consensus than controversy.
Ong, H. T. (2008) · PubMed · Cited by 8
Phaeochromocytoma and Acute Myocardial Infarction
Biccard, B. M., & Gopalan, P. (2002) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0203000114 · Cited by 7
β-Blocking Agents
Opie, L. H., & Horowitz, J. D. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-6158-8.50006-x · Cited by 7

Authors: Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J.
Affiliations: University of York (GB)
University of Hull (GB)
Corresponding author: Freemantle, N.
ORCID: Freemantle, N.
Cleland, J.
Mason, J.
Venue: BMJ
Publisher: BMJ
Published: 1999-06-26
Volume: 318
Issue: 7200
Pages: 1730-1737
ISSN: 0007-1447 (ISSN-L)
0959-8138
1468-5833
DOI: 10.1136/bmj.318.7200.1730
PMC: PMC31101
OpenAlex: W2070568974
Cited by: 1,509
References: 34
Citations by year: 2026: 27 · 2025: 43 · 2024: 38 · 2023: 30 · 2022: 42 · 2021: 36 · 2020: 49 · 2019: 47 · 2018: 53 · 2017: 57 · 2016: 58 · 2015: 48 · 2014: 67 · 2013: 74 · 2012: 83
FWCI: 7.55
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: BMJ (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
Keywords: beta-blockers, myocardial infarction, secondary prevention, all-cause mortality, reinfarction, cardioselectivity, intrinsic sympathomimetic activity, propranolol, timolol, metoprolol, number needed to treat, predictors of treatment response
MeSH terms: Adrenergic beta-Antagonists, Humans, Myocardial Infarction, Regression Analysis, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

beta Blockade after myocardial infarction: systematic review and meta regression analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks